DCF — NUERODIAGNOSTIC INSTITUTE
Enterprise Value: $-25.9M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-25.9M
Enterprise Value
$-8.7M
PV of Cash Flows
$-17.2M
PV of Terminal Value
$-27.8M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $30.2M | $-1.4M | -5.0% | $-2.6M | $-2.4M |
| Year 2 | $31.1M | $-1.1M | -4.0% | $-2.4M | $-2.0M |
| Year 3 | $32.0M | $-0.8M | -3.0% | $-2.2M | $-1.6M |
| Year 4 | $33.0M | $-0.7M | -2.0% | $-2.1M | $-1.4M |
| Year 5 | $33.9M | $-0.6M | -2.0% | $-2.0M | $-1.3M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-25.9M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$29.3M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.05000001195361192
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5